GEORGE ISRAEL GORODESKI
Medical Practice in Cleveland, OH
License number
Pennsylvania MD040614L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Cleveland, OH 44122
Pennsylvania
Pennsylvania
Personal information
See more information about GEORGE ISRAEL GORODESKI at radaris.comName
Address
Phone
25154 Bridgeton Dr, Cleveland, OH 44122
25154 Bridgeton Dr, Beachwood, OH 44122
Professional information
Dr. George I Gorodeski, Cleveland OH - MD (Doctor of Medicine)
Specialties:
Reproductive Endocrinology & Infertility
Address:
University OB/GYN
11100 Euclid Ave SUITE 1200, Cleveland 44106
(216) 844-3941 (Phone)
11100 Euclid Ave SUITE 1200, Cleveland 44106
(216) 844-3941 (Phone)
Languages:
English
Hospitals:
University OB/GYN
11100 Euclid Ave SUITE 1200, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
11100 Euclid Ave SUITE 1200, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
Education:
Medical School
Sackler School Of Medicine, Tel Aviv University
Graduated: 1972
Sackler School Of Medicine, Tel Aviv University
Graduated: 1972
George Israel Gorodeski, Cleveland OH
Specialties:
Reproductive Endocrinologist
Address:
11100 Euclid Ave, Cleveland, OH 44106
Screening, Diagnosing, Treating And Prognosis Of Pathophysiologic Status By Rna Regulation
US Patent:
2010019, Aug 5, 2010
Filed:
Mar 13, 2008
Appl. No.:
12/450124
Inventors:
George Gorodeski - Beachwood OH, US
Judith Potashkin - gurnee IL, US
Bentley Cheatham - Durham NC, US
Judith Potashkin - gurnee IL, US
Bentley Cheatham - Durham NC, US
Assignee:
UNIVERSITY OF CLEVELAND - Cleveland OH
ROSILAND FRANKLIN UNIVERSITY OF MEDICINE AND SCIEN - North Chicago IL
RIBONOMICS, INC. - Durham NC
ROSILAND FRANKLIN UNIVERSITY OF MEDICINE AND SCIEN - North Chicago IL
RIBONOMICS, INC. - Durham NC
International Classification:
C12Q 1/68, C07H 21/02, G01N 33/567
US Classification:
435 6, 536 231, 435 721
Abstract:
A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2XmRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.
Cell Collection And Disease Screening
US Patent:
2007028, Dec 13, 2007
Filed:
Jun 7, 2007
Appl. No.:
11/810916
Inventors:
George Gorodeski - Beachwood OH, US
Richard Domanik - Libertyville IL, US
Richard Domanik - Libertyville IL, US
International Classification:
C12Q 1/68, G01N 33/574, A61M 31/00
US Classification:
435006000, 435007230, 604500000
Abstract:
The present application discloses methods and tools for collecting cells to screen for disease, such as cancer. In one method of screening for a disease a flush fluid is injected into a human cavity, such as a uterus. The flush fluid and entrained cells from the cavity are withdrawn from the cavity and collected. The intermixed cells may be separated from the fluid and analyzed to determine whether the cells have a characteristic that is indicative of the presence of a disease. One tool for applying and withdrawing a fluid includes a nozzle, a screening fluid supply and fluid withdrawal mechanism. The nozzle includes an inlet port and an outlet port. The screening fluid supply supplies a screening fluid through the outlet port. The withdrawal mechanism withdraws fluid through the outlet port.
Method And Apparatus For Applying Medication To Internal Tissue
US Patent:
2007013, Jun 14, 2007
Filed:
Oct 21, 2004
Appl. No.:
10/576214
Inventors:
George Gorodeski - Beachwood OH, US
International Classification:
A61K 9/22
US Classification:
604892100
Abstract:
A method and apparatus for applying medication to internal human tissue. One drug delivery member () for applying medication () to internal human tissue includes a medication impermeable barrier () and a medication-carrying matrix (). The medication impermeable barrier is shaped to conform to a contour of the internal tissue. The medication-carrying matrix releases the medication to the human tissue upon being applied to the internal human tissue. The matrix may be adapted to adhere to the internal human tissue.
Truncated Proteins As Cancer Markers
US Patent:
2007002, Jan 25, 2007
Filed:
Jun 2, 2006
Appl. No.:
11/446420
Inventors:
George Gorodeski - Beachwood OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US
International Classification:
G01N 33/574, C07H 21/04, C12P 21/06, C07K 16/30, C07K 14/82
US Classification:
435007230, 435069100, 435320100, 435325000, 530350000, 530388800, 536023500
Abstract:
Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2Xprotein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2Xin cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2Xin cells are described.
Truncated Proteins As Cancer Markers
US Patent:
8518652, Aug 27, 2013
Filed:
Apr 28, 2010
Appl. No.:
12/769433
Inventors:
George Gorodeski - Beachwood OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US
Ying-Hong Feng - Germantown MD, US
Xin Li - Solon OH, US
Assignee:
Uniformed Services University of the Health Sciences, an Institution of Higher Learning within the Department of Defense. - Washington DC
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD
International Classification:
G01N 33/53, C07K 16/18
US Classification:
435 71, 5303879
Abstract:
Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2Xprotein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2Xin cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2Xin cells are described.
P2Xinhibition Of Epithelial Cancers And Papillomas
US Patent:
8314068, Nov 20, 2012
Filed:
Sep 4, 2009
Appl. No.:
12/554444
Inventors:
George Gorodeski - Beachwood OH, US
Wen Fu - Broadview Ht OH, US
Wen Fu - Broadview Ht OH, US
Assignee:
University Hospitals of Cleveland - Cleveland OH
International Classification:
A61P 35/00, C07K 14/705
US Classification:
514 189, 514 192, 514 193
Abstract:
The present invention demonstrates that P2Xreceptor induced apoptosis may be specific for cancerous cells. Treatment with the P2Xligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of developed papillomas and stimulated apoptosis in keratinocytes outgrowing at the base of developed papillomas. These data show that (a) P2Xregulates apoptosis of epidermal cells; (b) in vivo, local administration of a drug that activates the P2Xreceptor can inhibit development and progression of epidermal premalignant lesions.
P2X7: Inhibition Of Epithelial Cancers And Papillomas
US Patent:
2014003, Feb 6, 2014
Filed:
Sep 25, 2012
Appl. No.:
13/626154
Inventors:
George Gorodeski - Beachwood OH, US
Wen Fu - Broadview OH, US
Wen Fu - Broadview OH, US
International Classification:
A61K 31/7076, A61K 38/19
US Classification:
424 851, 514 47
Abstract:
The present invention demonstrates that P2Xreceptor induced apoptosis may be specific for cancerous cells. Treatment with the P2Xligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of developed papillomas and stimulated apoptosis in keratinocytes outgrowing at the base of developed papillomas. These data show that (a) P2Xregulates apoptosis of epidermal cells; (b) in vivo, local administration of a drug that activates the P2Xreceptor can inhibit development and progression of epidermal premalignant lesions.
Timing Of Ovulation Based On Vaginal Ph
US Patent:
2008007, Mar 20, 2008
Filed:
Aug 31, 2005
Appl. No.:
11/574279
Inventors:
George Gorodeski - Beachwood OH, US
Chung Liu - Cleveland Heights OH, US
Chung Liu - Cleveland Heights OH, US
International Classification:
A61B 10/00
US Classification:
600551000
Abstract:
A method of diagnosing ovulation in a female mammal comprises measuring the pH of the ectocervix of the female mammal and comparing the pH measured of the ectocervix to a reference value.